Eli Lilly and Company (NYSE:LLY) Stock Price Down 2.3% – What’s Next?

Eli Lilly and Company (NYSE:LLY)’s stock price fell 2.3% during mid-day trading on Tuesday . The stock traded as low as $1,140.74 and last traded at $1,154.27. 2,631,836 shares changed hands during mid-day trading, a decline of 17% from the average session volume of 3,187,436 shares. The stock had previously closed at $1,181.87.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Several recent reports and analyst actions remain constructive, including Guggenheim raising its price target and maintaining a buy rating, with other major firms also issuing elevated targets. Bullish commentary points to continued revenue growth and confidence in Lilly’s drug pipeline. Guggenheim Raises Eli Lilly PT
• Positive Sentiment: Coverage focused on Lilly’s weight-loss portfolio notes that its obesity drugs are generating a large share of revenue, reinforcing the market’s long-term growth thesis for the company. Eli Lilly’s Weight-Loss Drugs Are Worth to Investors
• Neutral Sentiment: The company also drew interest around new Kisunla data presented at the AAIC, which keeps Lilly in the spotlight for its Alzheimer’s franchise but is not yet a clear near-term catalyst by itself. Eli Lilly Presents New Kisunla Data
• Neutral Sentiment: One Forbes piece asks whether LLY can reach $2,090, reflecting continued optimism about the stock’s longer-term upside rather than a new fundamental development. Is Lilly Stock On Track To Hit $2,090?
• Negative Sentiment: Investor concern persists around competition in the billion-dollar obesity drug market, including a new article questioning whether a “disturbing trend” could hurt Lilly’s rollout of its weight-loss pill. That competition narrative may be weighing on sentiment. Bad News for Eli Lilly in the Billion-Dollar Obesity Drug Market

Analyst Ratings Changes

Several analysts recently weighed in on the company. Berenberg Bank increased their price target on Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the company a “hold” rating in a report on Monday, June 22nd. Wall Street Zen upgraded shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 2nd. Rothschild & Co Redburn increased their target price on shares of Eli Lilly and Company from $880.00 to $900.00 in a research note on Thursday, May 7th. JPMorgan Chase & Co. raised their target price on shares of Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the stock an “overweight” rating in a report on Tuesday, July 7th. Finally, Weiss Ratings raised shares of Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, July 1st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,271.93.

Eli Lilly and Company Stock Performance

The stock has a market cap of $1.09 trillion, a PE ratio of 41.00, a price-to-earnings-growth ratio of 1.47 and a beta of 0.51. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The firm has a 50 day moving average price of $1,103.63 and a 200 day moving average price of $1,034.03.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. During the same quarter in the prior year, the business earned $3.34 earnings per share. Eli Lilly and Company’s revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, research analysts forecast that Eli Lilly and Company will post 35.81 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be given a $1.73 dividend. The ex-dividend date is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is 24.58%.

Institutional Trading of Eli Lilly and Company

Several institutional investors have recently modified their holdings of LLY. Vanguard Group Inc. raised its stake in Eli Lilly and Company by 1.2% in the 4th quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock valued at $88,087,193,000 after purchasing an additional 1,006,885 shares during the last quarter. State Street Corp raised its stake in Eli Lilly and Company by 1.8% during the fourth quarter. State Street Corp now owns 35,361,916 shares of the company’s stock worth $38,002,744,000 after purchasing an additional 635,358 shares during the period. Morgan Stanley boosted its holdings in Eli Lilly and Company by 2.7% in the 4th quarter. Morgan Stanley now owns 15,593,019 shares of the company’s stock valued at $16,757,510,000 after purchasing an additional 407,166 shares during the last quarter. Capital World Investors grew its stake in shares of Eli Lilly and Company by 0.4% in the 4th quarter. Capital World Investors now owns 15,031,750 shares of the company’s stock valued at $16,154,619,000 after buying an additional 61,851 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its position in Eli Lilly and Company by 10.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,910,505 shares of the company’s stock worth $16,024,022,000 after acquiring an additional 1,432,069 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.